mTOR kinase inhibitors as potential cancer therapeutic drugs - Wikidata - wikimedia - TriplyDB

mTOR kinase inhibitors as potential cancer therapeutic drugs

mTOR kinase inhibitors as potential cancer therapeutic drugs

http://www.wikidata.org/entity/Q27027963

about

Targeting mTOR in Pancreatic Ductal Adenocarcinoma Role of mTOR Inhibitors in Kidney Disease Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance The multiple cellular functions of the oncoprotein Golgi phosphoprotein 3 Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.Glucose metabolism regulates T cell activation, differentiation, and functions.mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.Signaling mechanisms that suppress the cytostatic actions of rapamycin mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo.mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells Glutaminolysis and autophagy in cancer The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer Targeting the LKB1 tumor suppressor.The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation Gremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling.Targeting mTOR network in colorectal cancer therapy Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.Targeting the Mammalian Target of Rapamycin in Lung Cancer.Regulation of the epithelial Na+ channel by the mTORC2/SGK1 pathway.Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation.

P2860

Q26747291-5992E70F-A5A7-4017-9191-69873EBC8C82 Q26747506-325C1CFD-3E5D-4B23-8C9D-7129D06B27C2 Q28071388-3EF02808-D3D8-49E6-AEA3-30066A64ACCD Q28077347-DC98CE52-81EA-438B-9A6A-B78C16A4D57D Q28082896-8994F019-35E3-44D2-88AD-407ED729950C Q33645556-54307028-EA56-4631-80D7-65B5A3920B16 Q33709769-55A3A4A8-98AF-4252-A381-F93F89331D5A Q33728258-37A60467-E1E9-4B03-8A92-31C25A0922B3 Q34466148-97E70349-FCDF-40BA-9EA8-25A08EDFBB75 Q34999559-FE5BCAA3-1B75-4108-8345-B7E69385B015 Q35139024-BDF45D0A-8A85-4F58-8766-76F59BB230FD Q35187701-B9AFFF31-4033-4917-A958-68B379236B4F Q35562874-19B23DBD-8B65-49B9-A2E5-08D802B6CF17 Q35685586-4E44C549-5A96-4EF0-B33A-FA7743B19DA8 Q35708311-2722FCC2-22A4-438D-902D-7EFA14D13F5D Q35832276-290663C9-C802-4DAB-BE5E-1C842803AA12 Q36050424-A3F46AC5-978E-4A92-96B7-477189A93427 Q36111779-3CBEB2B4-160B-4FFE-AD56-ADCAD9F37EB2 Q36123027-24995D25-6EFB-4C7D-91E3-0B324B187C29 Q36187271-0D8A8D81-F2D7-4F2A-8EC8-ECD3AE3B8CA0 Q36189861-67B3D70B-038E-483B-80AB-859C7FA074D8 Q36215450-E3A19A57-D8D0-42FE-8465-982B5A2D2A8C Q36320156-F450FA12-8A3F-46F2-A5FF-5E3A3513B23C Q36547894-9C75447E-38D4-4D00-9B9D-C7836E8A7238 Q36650919-BBE0A0EC-7BBF-4A6A-954D-6B3B9429086A Q36744735-F0BF81F8-080A-4C46-AB88-22475BC4CE0B Q36916277-3CA473F2-074B-41A8-9BFE-E3463B854AFC Q37151073-B63BA089-0BF4-486D-A4CE-D597B727F047 Q37506032-E81390CB-AE8A-4D85-8D5F-29E45C59622E Q37580269-204E3D49-8FAF-48E2-8A0C-5D7CCB1028D3 Q37604295-6775C6EE-7E78-4A94-BB5F-EF1D58E9825B Q37702395-2756BFE8-4C06-4E51-83DC-75150B48DC7D Q37708005-86E5CA3E-28DD-4645-ADF1-6F645274CD1F Q37721031-A1E9D3E1-8860-4FBD-B76B-530E90664279 Q37741531-21AB5D1D-AFD2-4563-95B1-A6CB6E9AA3D4 Q38545109-25A269A4-A13F-415A-9651-935138B2116E Q38758962-3AC41EFA-6F31-4D5A-9776-DB43631B2B72 Q38792344-B3D5F2D1-C383-4525-A424-FF3A8C6AF587 Q38842150-0398698B-A935-458F-9515-3DDB8C0B6674 Q38843938-48FD5019-6B08-4B03-B83A-5B5C8CB17525

P2860

mTOR kinase inhibitors as potential cancer therapeutic drugs

http://www.wikidata.org/entity/Q27027963

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

mTOR kinase inhibitors as potential cancer therapeutic drugs

@ast

mTOR kinase inhibitors as potential cancer therapeutic drugs

@en

mTOR kinase inhibitors as potential cancer therapeutic drugs

@nl

type

label

mTOR kinase inhibitors as potential cancer therapeutic drugs

@ast

mTOR kinase inhibitors as potential cancer therapeutic drugs

@en

mTOR kinase inhibitors as potential cancer therapeutic drugs

@nl

prefLabel

mTOR kinase inhibitors as potential cancer therapeutic drugs

@ast

mTOR kinase inhibitors as potential cancer therapeutic drugs

@en

mTOR kinase inhibitors as potential cancer therapeutic drugs

@nl

P1433

Q27027963-8206653C-52D2-4249-BE83-21B08A5D15D4

P1476

Q27027963-FBCF2554-5A48-4844-867F-4384301129B7

P2093

Q27027963-17C52FE9-721D-45AE-B75D-2612AF10AC87

P2860

Q27027963-03C67EBB-C666-4079-8B5A-758F3D3F7DB1

Q27027963-05762E93-1976-4D19-ABD6-30C6D6682A07

Q27027963-07253771-B4F0-4BDB-82B4-126539976BD0

Q27027963-0B723549-8EF7-4E6F-9999-630BC128FF10

Q27027963-0D398AEB-7AB4-4FA7-9D59-3CF72FAAA516

Q27027963-1A817690-DB7B-45D8-A772-00086AF1394C

Q27027963-1BDB63D0-9AB2-4206-B9B4-69F95371C62A

Q27027963-1E15E434-4261-4327-A814-6570CE822C43

Q27027963-222A4C08-1426-438C-BD94-0293FB2AE772

Q27027963-2387C926-6305-461D-BC9C-2DBDE9827018

P304

Q27027963-C305B26A-B914-459C-AC64-B9D2A7B76F4A

P31

Q27027963-24F8F3B2-DBDA-404B-B8C0-4F7D6621CF09

P3181

Q27027963-F0553245-469E-4C3D-9339-68C9B249B205

P356

Q27027963-4D01B390-0723-4DF5-90F3-37D70DBDE06D

P407

Q27027963-07A65B52-B7B3-4604-901E-A9A646D47F5D

P433

Q27027963-1DB7AA48-7584-43B2-B05E-569DAA8CD42D

P478

Q27027963-C38E69C2-A57D-4268-89D4-0CF6574310E0

P577

Q27027963-72E6896E-D0B5-4145-B367-EE1F4E505A70

P698

Q27027963-FD6AEEE8-8C77-4A8E-A7E7-68F7F1DE25AA

P932

Q27027963-DE5E2497-4587-497E-B479-2EEE50E71FB5

P3181

P356

J.CANLET.2013.06.017

P1433

P1476

mTOR kinase inhibitors as potential cancer therapeutic drugs

@en

P2093

Shi-Yong Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

Defining the role of mTOR in cancer

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

621652

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CANLET.2013.06.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

340

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23792225

http://www.w3.org/2001/XMLSchema#string

P932

3779533

http://www.w3.org/2001/XMLSchema#string